Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC) and can have a significant impact on patient morbidity and quality of life. We assessed the effect of adalimumab (ADA) therapy on the resolution of EIMs among patients with moderate to severe UC in clinical pra...
Hoofdauteurs: | Travis, S, Feagan, B, Peyrin-Biroulet, L, Panaccione, R, Danese, S, Lazar, A, Robinson, A, Thakkar, R, Pappalardo, B, Petersson, J, Bereswill, M, Chen, N, Skup, M |
---|---|
Formaat: | Journal article |
Gepubliceerd in: |
Oxford University Press
2017
|
Gelijkaardige items
-
Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
door: Travis, S, et al.
Gepubliceerd in: (2017) -
Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
door: Travis, S, et al.
Gepubliceerd in: (2017) -
Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results From InspirADA.
door: Travis, S, et al.
Gepubliceerd in: (2017) -
The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
door: Sandborn, W, et al.
Gepubliceerd in: (2016) -
Does it all ADA up? Adalimumab for ulcerative colitis.
door: Travis, S
Gepubliceerd in: (2011)